Bonesupport Holding Management
Management criteria checks 3/4
Bonesupport Holding's CEO is Torbjorn Skold, appointed in Sep 2025, has a tenure of less than a year. total yearly compensation is SEK4.12M, comprised of 27.8% salary and 72.2% bonuses, including company stock and options. directly owns 0.023% of the company’s shares, worth SEK3.39M. The average tenure of the management team and the board of directors is 6 years and 4.1 years respectively.
Key information
Torbjorn Skold
Chief executive officer
SEK 4.1m
Total compensation
| CEO salary percentage | 27.77% |
| CEO tenure | less than a year |
| CEO ownership | 0.02% |
| Management average tenure | 6yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
Narrative Update • Jun 01
BONEX: Insider Buying And Profitability Trends Will Drive Future Upside
Analysts have slightly trimmed their price target for Bonesupport Holding to SEK 373.83 from SEK 377.17. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E.Narrative Update • May 13
BONEX: Infection Study Outcomes And Segment Focus Will Drive Future Upside
Analysts have kept their SEK price target for Bonesupport Holding broadly steady, with only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this latest narrative update. What's in the News Bonesupport Holding plans an analyst and investor day focused on how its segment based approach is intended to increase penetration and market share for CERAMENT in prioritized indication areas.Analysis Article • Apr 25
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Bonesupport Holding AB (publ) ( STO:BONEX ) missed earnings with its latest first-quarter results, disappointing...Narrative Update • Apr 23
BONEX: Clinical Pilot Infection Outcomes Will Support Future Upside Potential
Analysts have raised their price target for Bonesupport Holding by about SEK 10.60 to SEK 377.17, citing updated assumptions that include a slightly higher discount rate, adjusted revenue growth expectations, a revised profit margin outlook, and a lower future P/E multiple. What's in the News Bonesupport Holding announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma.Narrative Update • Apr 07
BONEX: Clinical Pilot Outcomes And 2026 Sales Outlook Will Support Future Upside Potential
Analysts have revised their price target on Bonesupport Holding to SEK 366.6. The update reflects an unchanged fair value along with adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Publication of a US clinical pilot study in OTA International highlighting surgical technique and outcomes for CERAMENT G in trauma cases, providing practical, real world guidance for clinicians considering the product in fracture related infections and osteomyelitis (Key Developments).Narrative Update • Mar 24
BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential
Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.
New Narrative • Mar 12
Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?Narrative Update • Mar 10
BONEX: Clinical Pilot Results And Strong Guidance Will Support Long-Term Upside Potential
Analysts have trimmed their price target on Bonesupport Holding by SEK 4 to SEK 366.6. This reflects updated assumptions around discount rates, revenue growth and profitability, while keeping future P/E expectations broadly in line with previous views. What's in the News Bonesupport announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma, giving clinicians practical, real world insights into its use in trauma cases.
New Narrative • Feb 25
US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products such as CERAMENT G and CERAMENT V, for use in complex bone infections and orthopedic procedures. What are the underlying business or industry changes driving this perspective?Narrative Update • Feb 23
BONEX: De Novo Shift Will Support Long Term Upside Potential
Analysts have slightly trimmed their fair value estimate for Bonesupport Holding to SEK370.6, from SEK374.6, reflecting minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, while keeping the overall thesis broadly intact. What's in the News Bonesupport issued earnings guidance for Q4 2025, with net sales expected at 313 MSEK at constant exchange rates, based on company guidance for that period (company guidance).Analysis Article • Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
Key Insights Bonesupport Holding's estimated fair value is kr293 based on 2 Stage Free Cash Flow to Equity Current...Narrative Update • Feb 08
BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK374.60 per share. The latest price target update mainly reflects small technical tweaks to the discount rate and future P/E assumptions rather than a shift in the core outlook.Narrative Update • Jan 22
BONEX: De Novo Review Shift Will Support Long Term Upside Potential
Analysts have trimmed their price target for Bonesupport Holding to SEK 374.60 from SEK 391.20, citing slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple. What's in the News Bonesupport Holding issued earnings guidance for the fourth quarter of 2025 with net sales expected at SEK 313 M, based on constant exchange rates (Corporate guidance).Narrative Update • Jan 07
BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK391.20, with only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This suggests their overall view on the company’s long term potential is essentially unchanged.Narrative Update • Dec 24
BONEX: De Novo Pathway Shift Will Support Strong Future Market Position
Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.Narrative Update • Dec 10
BONEX: Hip Infection Study Success Will Drive Stronger Future Clinical And Market Position
Analysts have modestly raised their price target on Bonesupport Holding to SEK 391.2 per share from SEK 391.2 per share, reflecting largely unchanged long term assumptions on the discount rate, revenue growth, profit margins and future valuation multiples. What's in the News Positive top line data from the CeraHip clinical study show that CERAMENT G enabled successful single stage revision surgery for periprosthetic joint infection of the hip, with no re infections reported over 24 months of follow up (Key Developments).Narrative Update • Nov 25
BONEX: Positive Study Results Will Support Improvements In Hip Infection Outcomes
Analysts have adjusted their price target for Bonesupport Holding, maintaining it at SEK 391.20. Recent evaluations indicate steady expectations in light of updated discount rates and continued confidence in the company's growth and profitability outlook.Analysis Article • Nov 22
Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
To the annoyance of some shareholders, Bonesupport Holding AB (publ) ( STO:BONEX ) shares are down a considerable 25...Narrative Update • Nov 07
BONEX: Clinical Study Results Will Drive Long-Term Patient Outcome Improvements
Bonesupport Holding's analyst price target has been updated downward from SEK 401.80 to SEK 391.20, as analysts factor in slightly softer revenue growth forecasts and a higher discount rate. What's in the News Bonesupport announced positive results from a clinical study showing significantly improved patient-reported outcomes for CERAMENT G in single-stage revision surgery for periprosthetic joint infection of the hip (Key Developments).Analysis Article • Oct 28
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
It's shaping up to be a tough period for Bonesupport Holding AB (publ) ( STO:BONEX ), which a week ago released some...Narrative Update • Oct 24
Positive Clinical Results And US Launch Will Drive Future Success
Analysts have revised their price target for Bonesupport Holding from SEK 419.75 to SEK 401.80. This change reflects adjustments to growth and profitability assumptions.Analysis Article • Aug 25
Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon
Bonesupport Holding AB (publ)'s ( STO:BONEX ) price-to-sales (or "P/S") ratio of 18.3x might make it look like a sell...Analysis Article • Jul 23
Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear
Bonesupport Holding AB (publ)'s ( STO:BONEX ) recent soft profit numbers didn't appear to worry shareholders, as the...Analysis Article • Jun 28
Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price
Key Insights The projected fair value for Bonesupport Holding is kr508 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Apr 28
Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report
It's been a good week for Bonesupport Holding AB (publ) ( STO:BONEX ) shareholders, because the company has just...
New Narrative • Mar 19
CERAMENT G's US Launch And CERAMENT V's FDA Submission Will Expand Global Presence
CERAMENT G's rapid U.S. penetration addresses a significant market need, likely causing notable revenue growth due to its strong clinical backing.Analysis Article • Mar 01
kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results
Shareholders of Bonesupport Holding AB (publ) ( STO:BONEX ) will be pleased this week, given that the stock price is up...Analysis Article • Oct 31
Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders
The market wasn't impressed with the soft earnings from Bonesupport Holding AB (publ) ( STO:BONEX ) recently. Our...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | SEK 185m |
| Dec 31 2025 | SEK 4m | SEK 1m | SEK 142m |
Compensation vs Market: Torbjorn's total compensation ($USD435.24K) is below average for companies of similar size in the Swedish market ($USD1.16M).
Compensation vs Earnings: Insufficient data to compare Torbjorn's compensation with company performance.
CEO
Torbjorn Skold (49 yo)
less than a year
Tenure
SEK 4,123,000
Compensation
Mr. Torbjorn Skold is Chief Executive Officer of Bonesupport Holding AB (publ) from September 1, 2025. He serves as Member of the Supervisory Board at aap Implantate AG since August 15, 2024. He served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | less than a year | SEK 4.12m | 0.023% SEK 3.4m | |
| Chief Financial Officer | 7.6yrs | SEK 3.01m | 0.11% SEK 15.8m | |
| Executive Vice President of Global R&D and Operations | 4.5yrs | no data | 0.038% SEK 5.6m | |
| Executive Vice President of Global Marketing | 3.4yrs | no data | 0.019% SEK 2.8m | |
| Executive Vice President of Human Resources | 8.7yrs | no data | 0.024% SEK 3.6m | |
| Executive VP of Medical & Clinical Affairs and Chief Medical Officer | 9.2yrs | no data | 0.16% SEK 24.4m | |
| GM & Executive VP of Commercial Operations of EUROW | 6.6yrs | no data | 0.028% SEK 4.2m | |
| GM & Executive VP of Commercial Operations of US | 6yrs | no data | 0.048% SEK 7.2m | |
| Executive Vice President of Quality Management & Regulatory Affairs | 1.9yrs | no data | 0.0038% SEK 564.1k |
6.0yrs
Average Tenure
55yo
Average Age
Experienced Management: BONEX's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | 16.4yrs | SEK 568.00k | 0.41% SEK 60.3m | |
| Independent Chairman of the Board | 9.4yrs | SEK 1.28m | 0.22% SEK 32.8m | |
| Director | 1.1yrs | SEK 329.00k | 0.0046% SEK 681.4k | |
| Independent Director | 4.1yrs | SEK 854.00k | 0.0050% SEK 746.7k | |
| Director | less than a year | SEK 8.32m | no data | |
| Independent Director | 4.1yrs | SEK 585.00k | 0.041% SEK 6.1m |
4.1yrs
Average Tenure
65yo
Average Age
Experienced Board: BONEX's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/09 06:09 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bonesupport Holding AB (publ) is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Erik Cassel | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |